With a street-high upside potential of 159.0%, Stereotaxis, Inc. (NYSE:STXS) ranks among the 10 best robotics stocks to buy under $30.
Photo by FRANCESCO TOMMASINI on Unsplash
The first time the company’s MAGiC catheter was used in the U.S., it did not ease into things gently. On April 22, 2026, Stereotaxis, Inc. (NYSE:STXS) saw its newly FDA-approved robotic magnetic ablation catheter go straight to work on some of the most difficult heart cases, successfully treating patients with complex congenital heart disease and severe cardiac arrhythmia at Oregon Health & Science University. The doctors were surprised as the catheter reached anatomical regions that legacy catheter technique attempts had simply failed to access.
The MAGiC system works within Stereotaxis, Inc. (NYSE:STXS)’s robotic magnetic navigation platform, enabling precise, computer-controlled catheter movement for minimally invasive cardiac ablation and opening the door to treatment for patient populations that have historically been underserved or considered too high-risk for conventional approaches. Early outcomes added further encouragement, with no recurrence of arrhythmia reported in treated patients within weeks of the procedures.
That clinical validation arrived alongside a separate but complementary strategic move.
On April 15, 2026, Stereotaxis, Inc. (NYSE:STXS) made its move, announcing a deal to take over Robocath, a European robotics company that works on robotic systems for heart and brain interventional procedures. Stereotaxis brings magnetic navigation to the table while Robocath brings mechanical automation engineering, together forming a much more complete robotic surgical platform.
Robocath provides Stereotaxis, Inc. (NYSE:STXS) with something tangible from day one. Its R-One+ system is already up and running across Europe, handing Stereotaxis an immediate commercial foothold on the continent.
On the numbers side, management has laid out a measured path forward: regulatory filings are on the calendar within two years, breakeven is projected within three years of closing, and the deal is projected to bring in $2 million in annual revenue.
Stereotaxis, Inc. (NYSE:STXS) designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its primary products are the Genesis RMN System, the Odyssey Solution, and other related devices.
While we acknowledge the risk and potential of STXS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than STXS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
